您当前所在的位置:首页 > 产品中心 > 产品信息
Vinflunine Ditartrate_分子结构_CAS_194468-36-5)
点击图片或这里关闭

Vinflunine Ditartrate

产品号 V314500 公司名称 Toronto Research Chemicals
CAS号 194468-36-5 公司网站 http://www.trc-canada.com
分子式 C49H60F2N4O14 电 话 +1 (416) 665-9696
分子量 967.0159064 传 真 +1 (416) 665-4439
纯 度 电子邮件 info@trc-canada.com
保 存 -20°C Freezer Chembase数据库ID: 179511

产品价格信息

请登录

产品别名

标题
Vinflunine Ditartrate
IUPAC标准名
(2R,3R)-2,3-dihydroxybutanedioic acid methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-4-[(12S,14S)-16-(1,1-difluoroethyl)-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
IUPAC传统名
L(+)-tartaric acid methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-4-[(1R,12S,14S)-16-(1,1-difluoroethyl)-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
别名
4'-Deoxy-20',20'-difluoro-5'-nor-vincaleukoblastine Ditartrate
(2β,3β,4β,5α,12β,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylic Acid Methyl Ester (2R,3R)-2,3-Dihydroxybutanedioate
BMS 710485
Javlor
20',20'-Difluoro-3',4'-dihydrovinorelbine Ditartrate
F 12158

产品登记号

CAS号 194468-36-5

产品性质

质检报告 下载链接
外观 White Solid
熔点 244-246°C (dec)
溶解度 DMSO
MSDS下载 下载链接
保存条件 -20°C Freezer

产品详细信息

详细说明 (English)
Vinflunine is a semisynthetic Vinca alkaloid with microtubule destabilizing and antiangiogenic activity. Vinflunine is a derivative of Vinorelbine. Vinflunine is used as an antineoplastic.

参考文献

  • Kruczynski, A., et al.: Crit. Rev. Oncol. Hematol., 40, 159 (2001)
  • Fabre, C., et al.: Biochem. Pharmacol., 64, 733 (2001)
  • Bennouna, J. et al.: Ann. Oncol., 14, 630 (2001)
  • Bennouna, J., et al.: Expert Opin. Invest. Drugs, 14, 1259 (2005).